Cargando…

Do caffeine and more selective adenosine A(2A) receptor antagonists protect against dopaminergic neurodegeneration in Parkinson’s disease?

The adenosine A(2A) receptor is a major target of caffeine, the most widely used psychoactive substance worldwide. Large epidemiological studies have long shown caffeine consumption is a strong inverse predictor of Parkinson’s disease (PD). In this review, we first examine the epidemiology of caffei...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Jiang-Fan, Schwarzschild, Michael A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8102090/ https://www.ncbi.nlm.nih.gov/pubmed/33349580 http://dx.doi.org/10.1016/j.parkreldis.2020.10.024

Ejemplares similares

Caffeine Protects Dopaminergic Neurons From Dopamine-Induced Neurodegeneration via Synergistic Adenosine-Dopamine D2-Like Receptor Interactions in Transgenic Caenorhabditis elegans
por: Manalo, Rafael V. M., et al.
Publicado: (2018)

Caffeine and Selective Adenosine Receptor Antagonists as New Therapeutic Tools for the Motivational Symptoms of Depression
por: López-Cruz, Laura, et al.
Publicado: (2018)

Do Naturally Occurring Antioxidants Protect Against Neurodegeneration of the Dopaminergic System? A Systematic Revision in Animal Models of Parkinson's Disease
por: Costas, Carmen, et al.
Publicado: (2022)

Ablation of RIP3 protects from dopaminergic neurodegeneration in experimental Parkinson’s disease
por: Dionísio, Pedro A., et al.
Publicado: (2019)

Uncovering Caffeine’s Adenosine A(2A) Receptor Inverse Agonism in Experimental Parkinsonism
por: Fernández-Dueñas, Víctor, et al.
Publicado: (2014)

Divergent Effects of the Nonselective Adenosine Receptor Antagonist Caffeine in Pre-Manifest and Motor-Manifest Huntington’s Disease
por: Achenbach, Jannis, et al.
Publicado: (2022)

Sorbus alnifolia protects dopaminergic neurodegeneration in Caenorhabditis elegans
por: Cheon, Se-Myeong, et al.
Publicado: (2016)

Parkinson's disease-linked mutations in VPS35 induce dopaminergic neurodegeneration
por: Tsika, Elpida, et al.
Publicado: (2014)

TFE3-Mediated Autophagy is Involved in Dopaminergic Neurodegeneration in Parkinson’s Disease
por: He, Xin, et al.
Publicado: (2021)

Cannabinoid Type 2 (CB(2)) Receptors Activation Protects against Oxidative Stress and Neuroinflammation Associated Dopaminergic Neurodegeneration in Rotenone Model of Parkinson's Disease
por: Javed, Hayate, et al.
Publicado: (2016)

Adenosine A(2A) Receptor Occupancy by Caffeine After Coffee Intake in Parkinson's Disease
por: Ishibashi, Kenji, et al.
Publicado: (2022)

Binding of the Antagonist Caffeine to the Human Adenosine Receptor hA(2A)R in Nearly Physiological Conditions
por: Cao, Ruyin, et al.
Publicado: (2015)

N-Acetyl Cysteine Protects against Methamphetamine-Induced Dopaminergic Neurodegeneration via Modulation of Redox Status and Autophagy in Dopaminergic Cells
por: Chandramani Shivalingappa, Prashanth, et al.
Publicado: (2012)

Adenosine A(2A) receptor antagonists act at the hyperoxic phase to confer protection against retinopathy
por: Zhou, Rong, et al.
Publicado: (2018)

The Pharmacological Potential of Adenosine A(2A) Receptor Antagonists for Treating Parkinson’s Disease
por: Mori, Akihisa, et al.
Publicado: (2022)

Caffeine and a selective adenosine A(2A )receptor antagonist induce sensitization and cross-sensitization behavior associated with increased striatal dopamine in mice
por: Hsu, Chih W, et al.
Publicado: (2010)

miR-425 deficiency promotes necroptosis and dopaminergic neurodegeneration in Parkinson’s disease
por: Hu, Yong-Bo, et al.
Publicado: (2019)

KD-64—A new selective A(2A) adenosine receptor antagonist has anti-inflammatory activity but contrary to the non-selective antagonist—Caffeine does not reduce diet-induced obesity in mice
por: Kotańska, Magdalena, et al.
Publicado: (2020)

Tetraspanin (TSP-17) Protects Dopaminergic Neurons against 6-OHDA-Induced Neurodegeneration in C. elegans
por: Masoudi, Neda, et al.
Publicado: (2014)

Sexually dimorphic mechanisms of VGLUT-mediated protection from dopaminergic neurodegeneration
por: Buck, Silas A., et al.
Publicado: (2023)

Selective adenosine A(2A )receptor agonists and antagonists protect against spinal cord injury through peripheral and central effects
por: Paterniti, Irene, et al.
Publicado: (2011)

Neuroprotective Effects of Thymol, a Dietary Monoterpene Against Dopaminergic Neurodegeneration in Rotenone-Induced Rat Model of Parkinson’s Disease
por: Javed, Hayate, et al.
Publicado: (2019)

Dopaminergic neurodegeneration in the substantia nigra is associated with olfactory dysfunction in mice models of Parkinson’s disease
por: Yuan, Yu, et al.
Publicado: (2023)

Angiotensin Type 1 Receptor Antagonists Protect Against Alpha-Synuclein-Induced Neuroinflammation and Dopaminergic Neuron Death
por: Rodriguez-Perez, Ana I., et al.
Publicado: (2018)

Effects of Adenosine Receptor Antagonists on the In Vivo LPS-Induced Inflammation Model of Parkinson’s Disease
por: Gołembiowska, Krystyna, et al.
Publicado: (2013)

Adenosine A(2A) Receptor Antagonists Affects NMDA Glutamate Receptor Function. Potential to Address Neurodegeneration in Alzheimer’s Disease
por: Franco, Rafael, et al.
Publicado: (2020)

α-Synuclein Aggregates in the Nigro-Striatal Dopaminergic Pathway Impair Fine Movement: Partial Reversal by the Adenosine A(2A) Receptor Antagonist
por: Cai, Qionghui, et al.
Publicado: (2023)

Caffeine reduces deficits in mechanosensation and locomotion induced by L-DOPA and protects dopaminergic neurons in a transgenic Caenorhabditis elegans model of Parkinson’s disease
por: Manalo, Rafael Vincent M., et al.
Publicado: (2020)

Mitochondrial angiotensin receptors in dopaminergic neurons. Role in cell protection and aging-related vulnerability to neurodegeneration
por: Valenzuela, Rita, et al.
Publicado: (2016)

Molecular and pharmacodynamic interactions between caffeine and dopaminergic system
por: Voiculescu, M, et al.
Publicado: (2014)

Mechanism of miR-132-3p Promoting Neuroinflammation and Dopaminergic Neurodegeneration in Parkinson’s Disease
por: Gong, Xin, et al.
Publicado: (2022)

The Crucial Roles of Pitx3 in Midbrain Dopaminergic Neuron Development and Parkinson’s Disease-Associated Neurodegeneration
por: Wang, Xin, et al.
Publicado: (2023)

Caffeine Protects Against Retinal Inflammation
por: Conti, Federica, et al.
Publicado: (2022)

Effects of adenosine receptor antagonists in MPTP mouse model of Parkinson’s disease: mitochondrial DNA integrity
por: Essawy, Soha S., et al.
Publicado: (2017)

Adenosine A(2A) Receptor Antagonists Do Not Disrupt Rodent Prepulse Inhibition: An Improved Side Effect Profile in the Treatment of Parkinson's Disease
por: Bleickardt, Carina J., et al.
Publicado: (2012)

Squamosamide derivative FLZ protects dopaminergic neurons against inflammation-mediated neurodegeneration through the inhibition of NADPH oxidase activity
por: Zhang, Dan, et al.
Publicado: (2008)

Protection from α-Synuclein induced dopaminergic neurodegeneration by overexpression of the mitochondrial import receptor TOM20
por: De Miranda, Briana R., et al.
Publicado: (2020)

Sex Differences and Caffeine Impact in Adenosine-Induced Hyperemia
por: Lassen, Martin Lyngby, et al.
Publicado: (2022)

Interleukin-4 Protects Dopaminergic Neurons In vitro but Is Dispensable for MPTP-Induced Neurodegeneration In vivo
por: Hühner, Laura, et al.
Publicado: (2017)

Substantia Nigra Hyperechogenicity Reflects the Progression of Dopaminergic Neurodegeneration in 6-OHDA Rat Model of Parkinson’s Disease
por: Zhang, Siyan, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_43ejhr4qtbfd2v8vuol4c8m3h8